Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents

MLA

Sangmin Lee, et al. “Oral Eltanexor Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents.” Journal of Hematology & Oncology, vol. 15, Aug. 2022. EBSCOhost, https://doi.org/10.1186/s13045-022-01319-y.

APA

Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge, Fan Yang, Erkan Baloglu, Jatin Shah, Michael G. Kauffman, Sharon Shacham, & Bhavana Bhatnagar. (2022). Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents. Journal of Hematology & Oncology, 15. https://doi.org/10.1186/s13045-022-01319-y

Chicago

Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge, Fan Yang, Erkan Baloglu, et al. 2022. “Oral Eltanexor Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents.” Journal of Hematology & Oncology 15 (August). doi:10.1186/s13045-022-01319-y.